Alembic Pharmaceuticals has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Doxycycline Hyclate Tablets USP 100mg.
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Vibra-Tabs, 100mg of Pfizer, Inc. Doxycycline Hyclate Tablets USP 100mg should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
Doxycycline Hyclate Tablets 100mg have an estimated market size of US$ 53 million for twelve months ending December 2019 according to IQVIA.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
